Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ASCO 2026 | Werner helicase inhibitors: looking beyond immunotherapy for MSI tumors

Timothy Yap • 4 Jun 2026

ASCO 2026

General Checkpoint Inhibitors

Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the development of Werner helicase inhibitors in microsatellite instability high (MSI-H) and mismatch repair deficient (dMMR) tumors. Prof. Yap explores the effectiveness of immune checkpoint inhibitors in patients with MSI-H or dMMR tumors, the mechanism of action of Werner helicase inhibitors, preclinical data, and trials which are exploring these therapies in patients. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.